Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...

After revolutionizing the weight-loss drug market, Novo Nordisk (NVO) and Eli Lilly (LLY) are setting their sights on heart ...

Novo Nordisk’s attempt to create a successor to its weight loss blockbuster Wegovy may have taken a hit with recent ...

Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new obesity ...

as we look to develop a broad portfolio of differentiated treatment options that cater to the diverse needs of people living ...

Under terms of the license agreement, Novo Nordisk will acquire the rights to develop and commercialize UBT251 outside of ...

Novo Nordisk already has a fairly well-stocked pipeline of candidates, but one of its near-term hopes – CagriSema, which ...

Bagsværd, Denmark Tuesday, April 1, 2025, 18:00 Hrs [IST] ...

Novo Nordisk has said will be gaining exclusive worldwide rights to United Laboratories International’s investigational ...

Novo Nordisk (NVO) says its obesity drug Ozempic improved walking distance for diabetes patients with peripheral artery ...

Novo Nordisk, which has led the obesity drug market ... 7:06 PM UTC · Updated ago Aerospace & Defensecategory Lockheed Martin clinches $4.94 billion US Army missile contract 7:08 PM UTC ...